Citation

Basit S., Ashraf Z., Lee K., Latif M.: First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib. European Journal of Medicinal Chemistry, Volume 134, 2017

Authors

Sulman Basit, Zaman Ashraf, Kwangho Lee, Muhammad Latif

Journal

European Journal of Medicinal Chemistry

Year

2017

DOI

10.1016/j.ejmech.2017.04.032

Machine-readable

REST APIRDF